Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 4344

1.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
[PubMed - indexed for MEDLINE]
Free Article
2.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
[PubMed - indexed for MEDLINE]
3.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

PMID:
20550659
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.

Breuer HW.

Curr Med Res Opin. 2001;17(1):60-73. Review.

PMID:
11464448
[PubMed - indexed for MEDLINE]
5.

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.

PMID:
16259526
[PubMed - indexed for MEDLINE]
6.

Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.

Alagona P Jr.

Am J Manag Care. 2009 Mar;15(3 Suppl):S65-73. Review.

PMID:
19355805
[PubMed - indexed for MEDLINE]
Free Article
7.

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C; European Consensus Panel on HDL-C.

Curr Med Res Opin. 2004 Aug;20(8):1253-68. Review.

PMID:
15324528
[PubMed - indexed for MEDLINE]
8.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
[PubMed - indexed for MEDLINE]
9.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
[PubMed - indexed for MEDLINE]
10.

Perspectives on low-density lipoprotein cholesterol goal achievement.

Catapano AL.

Curr Med Res Opin. 2009 Feb;25(2):431-47. doi: 10.1185/03007990802631438 . Review.

PMID:
19192988
[PubMed - indexed for MEDLINE]
11.

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.

Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH.

Am J Cardiovasc Drugs. 2008;8(2):69-81.

PMID:
18422390
[PubMed - indexed for MEDLINE]
12.

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Chrysant SG, Ibrahim M.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. Review.

PMID:
16849903
[PubMed - indexed for MEDLINE]
13.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Postgrad Med J. 2008 Nov;84(997):590-8. doi: 10.1136/hrt.2007.125401. Review.

PMID:
19103817
[PubMed - indexed for MEDLINE]
14.

Risk of cardiovascular events in patients at optimal values for combined lipid parameters.

Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ.

Curr Med Res Opin. 2007 Mar;23(3):553-63.

PMID:
17357251
[PubMed - indexed for MEDLINE]
15.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
[PubMed - indexed for MEDLINE]
16.

Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.

Isles CG, Paterson JR.

QJM. 2000 Sep;93(9):567-74. Review.

PMID:
10984551
[PubMed - indexed for MEDLINE]
Free Article
17.

Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.

Shepherd J, Betteridge J, Van Gaal L; European Consensus Panel.

Curr Med Res Opin. 2005 May;21(5):665-82. Review.

PMID:
15969866
[PubMed - indexed for MEDLINE]
18.

Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk.

Koeller J, Talbert RL.

Pharmacotherapy. 2002 Oct;22(10):1266-77. Review.

PMID:
12389877
[PubMed - indexed for MEDLINE]
19.

Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.

Chapman MJ.

Cardiovasc Drugs Ther. 2005 Mar;19(2):135-9. Review.

PMID:
16025232
[PubMed - indexed for MEDLINE]
20.

Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.

Boden WE.

Curr Opin Cardiol. 2003 Jul;18(4):278-85. Review.

PMID:
12858126
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk